Animal studies have further shown that hyperuricemia can result from the activation of mineralocorticoid receptors via mineralocorticoid and glucocorticoid pathways, a process that can be moderated by mineralocorticoid receptor blockers (35, 36). Here, NR3C2 is linked to hyperuricemia.